207_Combined course Presentations

Toxicity of concurrent SRT and immune checkpoint inhibition

Anti-PD-1/PD-L1 (nivolumab, pembrolizumab)

 Data on combined SRT and nivolumab is insufficient for conclusions, both for cranial and extra-cranial SRT.

 Data about the combination of pembrolizumab with SRT is not available.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37